Form 4: 10x Genomics CEO Sells Shares to Cover Tax Obligations
Insider Transaction Report
Serge Saxonov, CEO and Director of 10x Genomics, Inc., reported the sale of 9,343 shares of Class A Common Stock to satisfy tax withholding obligations related to restricted stock unit vesting.
Summary
- Serge Saxonov, Chief Executive Officer and Director of 10x Genomics, Inc. (TXG), filed a Form 4 reporting a transaction.
- On May 22, 2025, Mr. Saxonov sold 9,343 shares of Class A Common Stock.
- The shares were sold at a price of $8.2993 per share.
- The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following this transaction, Mr. Saxonov directly beneficially owns 1,083,625 shares of Class A Common Stock.
- Additionally, Mr. Saxonov indirectly beneficially owns shares through several trusts for which he serves as trustee: 27 shares via the Andromeda Trust, 870 shares via the Sirius Trust, 213,250 shares via the Y/S Descendants' Trust, and 22,570 shares via the Y/S Pot Trust.
Sentiment
Score: 5
Explanation: The transaction is a routine 'sell to cover' for tax obligations, which is a neutral event and does not indicate a change in management's sentiment towards the company's prospects.
Future Outlook
This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.
Industry Context
This filing is a routine insider transaction report common across all publicly traded companies, reflecting a standard practice for executives to cover tax liabilities upon the vesting of equity awards. It does not provide specific insights into broader industry trends in the life sciences or genomics sector.
Related Party Transactions
- Serge Saxonov indirectly holds shares through the Andromeda Trust (27 shares), Sirius Trust (870 shares), Y/S Descendants' Trust (213,250 shares), and Y/S Pot Trust (22,570 shares), for which he serves as trustee.
Stakeholder Impact
- Shareholders: The sale of a relatively small number of shares for tax purposes by a key executive is a routine event and is unlikely to have a significant impact on existing shareholders.
- Employees: No direct impact on employees is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 05/22/2025 | Date of transaction (sale of Class A Common Stock) |
| 05/27/2025 | Date the Form 4 was signed by Eric S. Whitaker, as Attorney-in-Fact for Serge Saxonov |
Keywords
10x Genomics, TXG, Serge Saxonov, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.